Prognostic impact of systolic blood pressure and antithrombotic strategy in patients with atrial fibrillation and stable coronary artery disease: a post-hoc analysis of the AFIRE trial
Lower SBP was associated with increased risk of cardiovascular events and all-cause death. Rivaroxaban monotherapy demonstrated more favorable efficacy and safety outcomes particularly patients with lower SBP.
Authors
- Takumi Higuma (ORCID: https://orcid.org/0000-0001-9156-0262)
- Kotaro Nochioka (ORCID: https://orcid.org/0000-0001-8297-8624)
- Shinichi Yamanaka
- Katsumi Miyauchi
- Takashi Noda (ORCID: https://orcid.org/0000-0001-9731-6842)
- Tetsuya Matoba (ORCID: https://orcid.org/0000-0003-4563-304X)
- Koichi Kaikita (ORCID: https://orcid.org/0000-0003-2962-8056)
- Masato Nakamura
- Satoshi Yasuda
- On Behalf Of The Afire Investigators
- Hisao Ogawa
- Nobuhisa Hagiwara
- Kunihiko Matsui
- Junya Ako
- Kazuo Kimura
- Masaharu Akao
Institutions
- University of Miyazaki (JP)
- Toho University (JP)
- Kyushu University (JP)
- Tohoku University (JP)
- Yokohama City University Medical Center (JP)
- Kyoto Medical Center (JP)
- Juntendo University (JP)
- Toho University Ohashi Medical Center (JP)
- Kindai University Hospital (JP)
- Kawasaki Municipal Hospital (JP)
- Kumamoto University Hospital (JP)
- Tokyo Women's Medical University (JP)
- Tokyo Metropolitan Geriatric Hospital (JP)
- Kitasato University (JP)
- Yokohama City University (JP)
- Kumamoto University (JP)
Publication Details
- Journal
- Hypertension Research
- Published
- 2026-01-05
- DOI
- https://doi.org/10.1038/s41440-025-02449-9
- Citations
- 1
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 30.07
Funders
- Amgen
- Bristol-Myers Squibb
- AstraZeneca
- Sanofi
- Boston Scientific Corporation
- Japan Agency for Medical Research and Development
- Japan Cardiovascular Research Foundation
- Kowa Company
- Boehringer Ingelheim Japan
- Daiichi-Sankyo
- Eisai
- Astellas Pharma
- Otsuka Pharmaceutical
- Novartis Pharma
- Bayer Yakuhin
- Amgen Astellas Biopharma
- Medtronic Japan